S095031-178: Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

This clinical trial is studying two different investigational treatments for patients with a blood disorder called myelodysplastic syndromes (MDS) who have a specific genetic mutation (IDH1) and have not been treated with certain drugs before. The study will compare the effects of two study drugs, Ivosidenib (IVO) and Azacitidine (AZA), given separately, to see how well they help patients. Researchers will track how many patients experience improvements, how long the treatment effects last, and overall survival.